Absolutely agree , with their IP clock running down and already in the business of Selling mTOR Pathway drugs they would be a door PAA should be knocking on,, after all PAA wont be taking MPL to market their Business strategy is to license...
Pfizer knows and understands the mTOR Pathway comprehensively , plus Roger has relationships with Pfizer , they purchase RAP earlier this year.
The three current mTOR Pathway drugs on market are from Pfizer and Novartis
1) Rapamune (Rapamycin) – sirolimus (Pfizer): kidney rejection – tested in
cancers:
2015 sales = US $200 million
2) Afinitor - everolimus (Novartis): European Medicines Agency for renal cell
carcinoma: 2015 annual sales = US $300 million
3) Torisel - temsirolimus (Pfizer): EMA approval for renal cell carcinoma
2015 annual sales = US $300 million
Absolutely agree , with their IP clock running down and already...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 376984 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 25091 | 2 |
View Market Depth
| Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |